coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Efficacy and safety of co-administered
Efficacy and safety of co administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Combined GLP 1 amylin analog bests monotherapy for HbA1c drop, weight loss in diabetes Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed
Pay in 4 interest-free payments of $6.56 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
00402-4/asset/7d856d37-1b1d-4481-9723-c6f28077488d/main.assets/gr2_lrg.jpg)



